人类抗体VH域针对PAR作为癌症候选治疗药物
Xiaojie Chu1, Wei Li1, Margaret G Hines1
1Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, United States.
Frontiers in oncology
|October 25, 2023
概括
针对尿素酶等离子体激活受体 (uPAR) 的两个新型人类VH域抗体显示出对癌症免疫疗法的前景. 这些抗体,当被设计成两种特异性的T细胞参与者时,有效地杀死UPAR阳性癌细胞.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物技术是生物技术.
背景情况:
- 泌尿酸酶等离子体激活受体 (uPAR) 在各种癌症中高度表达,与瘤进展,入侵和转移相关.
- uPAR过度表达为开发跨多种癌症类型的新型免疫疗法提供了重要的治疗标.
研究的目的:
- 为了识别和表征高亲和度的人类VH域抗体对PAR.
- 为了评估与这些抗-uPAR抗体设计的双特异性T细胞参与剂 (DbTEs) 在消除癌细胞方面的疗效.
主要方法:
- 从菌体显示库中分离人类VH域抗体候选物 (克隆3和115).
- 构建和测试基于域的双特异性T细胞参与者 (DbTEs),利用选择的抗uPAR抗体.
主要成果:
- 成功分离了针对UPAR的两个特定和高亲和度的人类VH域抗体克隆 (3和115) .
- 开发的DBTE在实验室中显示出强烈的细胞毒性作用,对抗UPAR阳性癌细胞.
结论:
- 已识别的抗-uPAR VH域抗体是开发向癌症免疫疗法的有效组件.
- 这些抗体代表了一系列Upar阳性恶性瘤的治疗有前途的治疗候选者.
更多相关视频
00:09Single-cell Screening Method for the Selection and Recovery of Antibodies with Desired Specificities from Enriched Human Memory B Cell Populations
Published on: August 22, 2019
10.8K
11:10Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study
Published on: June 29, 2016
14.1K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Hybridoma Technology
14.8K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.8K
